Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response

Jie Zhao, Xiufang Weng, Sreya Bagchi, and Chyung-Ru Wang

Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611

Edited* by Peter Cresswell, Yale University School of Medicine, New Haven, CT, and approved January 13, 2014 (received for review December 23, 2013)

CD1d-restricted natural killer T (NKT) cells are innate-like T cells with potent immunomodulatory function via rapid production of both Th1 and Th2 cytokines. NKT cells comprise well-characterized type I NKT cells, which can be detected by α-galactosylceramide-loaded CD1d tetramers, and less-studied type II NKT cells, which do not recognize α-galactosylceramide. Here we characterized type II NKT cells on a polyclonal level by using a Jκ18-deficient IL-4 reporter mouse model. This model allows us to track type II NKT cells by the GFPα+TCRβ+ phenotype in the thymus and liver. We found type II NKT cells, like type I NKT cells, exhibit an activated phenotype and are dependent on the transcriptional regulator promyelocytic leukemia zinc finger (PLZF) and the adaptor molecule signaling lymphocyte activation molecule-associate protein (SAP) for their development. Type II NKT cells are potently activated by β-glucopyranosylceramide (β-GlcCer) but not sulfatide or phospholipids in a CD1d-dependent manner, with the stimulatory capacity of β-GlcCer influenced by acyl chain length. Compared with type I NKT cells, type II NKT cells produce lower levels of IFN-γ but comparable amounts of IL-13 in response to polyclonal T-cell receptor stimulation, suggesting they may play different roles in regulating immune responses. Furthermore, type II NKT cells can be activated by CpG oligodeoxynucleotides to produce IFN-γ, but not IL-4 or IL-13. Importantly, CpG-activated type II NKT cells contribute to the antitumor effect of CpG in the B16 melanoma model. Taken together, our data reveal the characteristics of polyclonal type II NKT cells and their potential role in antitumor immunotherapy.

Significance

Type I and type II natural killer T (NKT) cells are unique T-cell types with potent immunomodulatory functions. Because of lack of markers available to track type II NKT cells, this subset has not been as extensively studied as type I NKT cells. In this study we used a unique mouse model as a tool to decipher the developmental requirements, antigen specificity, and functional potential of type II NKT cells. We found that even though type I and type II NKT cells exhibited similar developmental needs, they were functionally distinct. In addition, we demonstrated a means of harnessing the therapeutic potential of these cells in cancer immunity by transforming their tumor-suppressive functions into a protective response.

Author contributions: J.Z. and C.-R.W. designed research; J.Z. and X.W. performed research; J.Z., X.W., S.B., and C.-R.W. analyzed data; and J.Z., S.B., and C.-R.W. wrote the paper.

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

†To whom correspondence should be addressed. E-mail: chyung-ru.wang@northwestern.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1323845111/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1323845111
contrast to type I NKT cells, the roles of type II NKT cells in tumor models are typically associated with suppression of tumor immunosurveillance through secretion of IL-13 (20-22). However, it is not clear whether CpG can skew type II NKT cells toward a Th1 immune response and the consequences of such a skewing on tumor immunity.

In this study we demonstrated that we could faithfully track polyclonal type II NKT cells in Jx18-deficient IL-4 reporter mice by their spontaneous GFP expression. We showed that type II NKT cells share similar surface phenotype and developmental requirements with type I NKT cells. Despite their differences in TCR usage, both NKT cell subsets can be potently activated by β-D-glucopyranosylceramide (β-GlcCer) containing C12:0 and C24:1 acyl chains. Interestingly, type II NKT cells produced more IL-13 relative to IFN-γ upon TCR stimulation compared with type I NKT cells. However, CpG treatment induced type II NKT cells to secrete IFN-γ but not IL-13, which in turn contributed to the antitumor effect of CpG in B16 melanoma. Hence, our findings not only unravel the characteristics of type II NKT cells at a polyclonal level but also demonstrate a means by which the immunosuppressive effects of type II NKT cells can be transformed into a protective response in the context of tumor immunity.

**Results**

The Majority of GFP^+TCRβ^+ Population in Thymus and Liver of Jx18^-4get Mice Are Type II NKT Cells. Type I NKT cells have been shown to constitutively contain IL-4 mRNA and are spontaneously fluorescent in naive IL-4 GFP enhanced transcript (4get) mice (23). Consistent with previous studies, we found that approximately 90% of hepatic type I NKT cells were GFP-positive in naive 4get mice (Fig. 1A). Because type II NKT cells contribute to the early burst of IL-4 induced by anti-CD3 (24), it is conceivable that they also constitutively express IL-4 transcripts and spontaneously express GFP in 4get mice. In fact, 4get mice had a population of GFP-expressing T cells that was CD1d/α-GalCer tetramer negative (Fig. 1A). To determine whether this population was type II NKT cells and therefore CD1d restricted, we compared GFP^+ TCRβ^+ cells in Jx18^-4get mice (lacking type I NKT cells) and CD1d^-4get mice (lacking type I and II NKT cells). We found that the percentage and absolute number of GFP^+ TCRβ^+ cells were decreased by 80–85% in the thymus and liver of CD1d^-4get mice compared with Jx18^-4get mice (Fig.1 B–D). Although Vα10^+ type I NKT cells were present in Jx18^-4get mice, they only represented approximately 1–2% of GFP^+ TCRβ^+ cells in these mice (Fig. S1). This indicated that the vast majority of GFP^+ T cells in the thymus and liver of Jx18^-4get mice were CD1d-restricted type II NKT cells.

A small population of GFP^+ T cells was also found in the spleen, lymph node, and intestine of Jx18^-4get mice. However, the difference between Jx18^-4get and CD1d^-4get mice was less profound in these organs, suggesting that like type I NKT cells, type II NKT cells are also enriched in the liver. We also compared the frequency of the NK1.1^+TCRβ^- population in Jx18^-4get and CD1d^-4get mice. NK1.1^+ TCRβ^+ cells in CD1d^-4get mice decreased by 70% in the thymus but only by 50–60% in the liver compared with Jx18^-4get mice (Fig. S2). Collectively, our data support the use of the GFP^+ TCRβ^+ phenotype as a reliable way to identify most polyclonal type II NKT cells in the thymus and liver of Jx18^-4get mice.

**Characterization of Surface Phenotype and TCR Repertoire of Type II NKT Cells.** To characterize the surface phenotype of polyclonal type II NKT cells, we examined the coreceptor use and activation marker expression on GFP^+ T cells in the liver of Jx18^-4get mice (hereafter referred to as 4get type II NKT cells). Similar to type I NKT cells, 4get type II NKT cells were either CD4^+ or CD4^-CD8^- (Fig. 1A and B) and exhibited an activated phenotype (CD69^hiCD44^hiCD62L^lo) (Fig. 1C). The majority of 4get type II NKT cells also expressed NK1.1 and CD122.

To determine the overall spectrum of TCR use by 4get type II NKT cells, we first analyzed their Vβ use by flow cytometry (Fig. 2D). We found that a large percentage (~50%) of 4get type II NKT cells expressed Vβ1.8/8.2, and the remaining 4get type II NKT cells expressed a diverse array of Vβ chains. Next we analyzed the Vα chain use of sorted 4get type II NKT cells by real-time PCR using a panel of Vα-specific primers (25, 26). Similar to type I NKT cells, polyclonal type II NKT cells expressed the Vα14 gene, 4get type II NKT cells expressed a variety of Vα genes, with the Vα8 gene (~20%) being most prevalent.

**β-GlCer is a Potent Self-Antigen for 4get Type II NKT Cells.** To explore the diversity of lipid antigens involved in the activation of type II NKT cells, we examined the stimulatory capacity of a panel of synthetic lipids on short-term 4get type II NKT cell cultures. We found that several types of lipids, including β-GlcCer, β-GalCer, and Lyso-PE, can stimulate 4get type II NKT cells to secrete significant amounts of IFN-γ when presented by CD1d-expressing mouse bone marrow-derived DCs (BMDCs) (Fig. 2E). This stimulatory effect was abolished when CD1d^-BMDCs were used as antigen-presenting cells (APCs). Similar to type I NKT cells, the recognition of β-GlcCer by 4get type II NKT cells showed a preference for β-GalCer C12:0 and C24:1 (27). In addition, β-GalCer more potently activated type II NKT cells than each corresponding β-GalCer, suggesting that carbohydrate head group as well as the N-acyl chain of glycolipids can affect their recognition by type II NKT cells. In contrast, none of the phospholipids tested has stimulatory activity, except Lyso-PE. We also found that 4get type II NKT cells did not produce a significant amount of cytokines in response to sulfatide stimulation, suggesting that the frequency of sulfatide-reactive type II NKT cells in 4get type II NKT cells was very low.

**PLZF and SAP Are Required for the Development of Type II NKT Cells.** The transcriptional regulator PLZF has been reported as a key factor in establishing the type I NKT cell lineage and effector functions (13, 14). Given the phenotypic similarity between type I and type II NKT cells, it is likely that the development of type II NKT cells might depend on the same transcriptional regulator. Consistent with this notion, we found that PLZF was highly expressed in thymic 4get type II NKT cells (Fig. 3A). To further bolster the dependency of type II NKT cell development on PLZF, Jx18^-4get mice were crossed with PLZF-deficient luxoid (PLZF^del/^-) mice. Indeed, we found that Jx18^-4get/PLZF^del/^- mice
Type II NKT cells have been shown to play opposing roles in tumor immunity (31). To better understand the functional potential of type II NKT cells, we compared the cytokine-producing capacity of sorted 4get\(^+\) type II NKT cells with that of type I NKT cells. We found that type I and type II NKT cells produced the same major cytokines, such as IFN-\(\gamma\), IL-4, IL-13, and GM-CSF, upon activation with anti-CD3 (Fig. 4A). Compared with type I NKT cells, type II NKT cells produced lower levels of IFN-\(\gamma\) and IL-4 but similar levels of IL-13 and GM-CSF in response to anti-CD3 stimulation. Additionally, 4get\(^+\) type II NKT cells produced substantial amounts of cytokines when stimulated with BMDCs from CD1dTg mice. Similar to anti-CD3 stimulation, less IFN-\(\gamma\), but comparable amounts of IL-13 and GM-CSF, were detected in cocultures of 4get\(^+\) type II NKT cells and CD1dTg BMDC, compared with cocultures containing type I NKT cells (Fig. 4B). This suggests that confirming 4get\(^+\) type II NKT cells are indeed CD1d-restricted.

To evaluate the cytokine-producing ability of type I and type II NKT cells in the same mice under the same stimulatory condition, we injected 4get mice with anti-CD3 mAb. Thirty minutes after injection, cytokine production by type I (GFP\(^{+}\)TCR\(^\beta\)) CD1d/\(\alpha\)-GalCer\(^+\) and type II (GFP\(^{+}\)TCR\(^\beta\)CD1d/\(\alpha\)-GalCer\(^+\)) NKT cells was determined by intracellular cytokine staining. Consistent with the results from in vitro assays, a lower proportion of type II NKT cells produced IFN-\(\gamma\) and IL-4 compared with type I NKT cells (Fig. 4C). In particular, the proportion of IL-13 and GM-CSF-producing type II NKT cells were similar to that of type I NKT cells. The distinct cytokine-producing capacity of these two NKT cell subsets suggests that they may play distinct roles in the regulation of immune responses.

CpG ODN Induces IFN-\(\gamma\) Production by Type II NKT Cells In Vitro and in Vivo. Efforts to modulate NKT cell effector functions have ranged from treatment for autoimmunity disease to antitumor immunotherapy (32). Among them, CpG ODN, a potent adjuvant in cancer immunotherapy, promotes the production of IFN-\(\gamma\), but not IL-4, by type I NKT cells (18). Furthermore, the CpG-activated type I NKT cells have been shown to contribute to protection against B16 melanoma (18, 33). However, the effect of CpG on type II NKT cells remains unknown. To address this question, we first examined the response of type II NKT cells to CpG-sensitized DCs in vitro. We found that type II NKT cells produced IFN-\(\gamma\), but not IL-4 or IL-13, in response to CpG-treated DCs. The production of IFN-\(\gamma\) was partially blocked by anti-CD1d antibody, indicating that full activation of type II NKT cells by CpG was dependent on CD1d (Fig. 5A). This response was inhibited by anti-CD1d, that confirming 4get\(^+\) type II NKT cells were similar to that of type I NKT cells. The distinct cytokine-producing capacity of these two NKT cell subsets suggests that they may play distinct roles in the regulation of immune responses.

Fig. 3. PLZF and SAP are required for the development of type II NKT cells. (A) Expression of PLZF (black line) on thymic type I and type II NKT cells and CD4 T cells, compared with isotype control (gray filled). (B and C) Liver MNCs from Jx18\(^−/−\)-4get mice, Jx18\(^−/−\)-PLZF\(^−/−\)4get mice (B), and Jx18\(^−/−\)-SAP\(^−/−\)4get mice (C) were stained with mAbs to CD4, NK1.1, and TCR\(^\beta\) and then analyzed by flow cytometry. Data are representative of three experiments.

Exhibited a drastic reduction (>40-fold) of 4get\(^+\) type II NKT cells compared with Jx18\(^−/−\)-4get mice (Fig. 3B). Concordantly, the CD4\(^+\)NK1.1\(^+\) T-cell population was also dramatically reduced in Jx18\(^−/−\)-PLZF\(^−/−\)4get mice.

The adaptor molecule SAP plays a crucial role during the development of type I NKT cells, with SAP-deficient humans and mice lacking type I NKT cells (28, 29). We found that SAP deficiency also significantly affected the development of type II NKT cells: the percentages of 4get\(^+\) type II NKT cells as well as CD4\(^+\)NK1.1\(^+\) T cells were reduced more than 10-fold in Jx18\(^−/−\)-SAP\(^−/−\)4get mice compared with Jx18\(^−/−\)-4get mice (Fig. 3C). Together, these data suggest that type II NKT cells may share a similar development program with type I NKT cells.
of type II NKT cells leads to transactivation of other cell types, the expression level of CD69 on various cell types and IFN-γ production of NK cells in WT, Jα18−/−, and CD1d−/− mice after CpG injection were compared. The expression level of CD69 on CD8+ T cells was increased in Jα18−/− mice compared with CD1d−/− mice, suggesting that CpG-activated type II NKT cells can transactivate CD8+ T cells but not other cell types (Fig. S5D). Additionally, the percentage of IFN-γ-producing NK cells was significantly higher in WT mice but comparable between Jα18−/− and CD1d−/− mice (Fig. S3D). Collectively, these data demonstrate that type II NKT cells can be activated by CpG to produce IFN-γ both in vitro and in vivo. Furthermore, CpG-mediated type II NKT cell activation can enhance the activation of CD8+ T cells.

Type II NKT Cells Enhance the Antitumor Effect of CpG in B16 Melanoma. To assess the role of type II NKT cells in CpG-mediated immunotherapy, WT, Jα18−/−, and CD1d−/− mice were inoculated s.c. with B16 melanoma cells, and tumor growth in PBS- or CpG-treated mice was monitored. CpG treatment significantly reduced tumor growth in all mouse strains tested (Fig. 6A). Notably, the tumor volume in CpG-treated Jα18−/− mice was significantly smaller than that in CpG-treated CD1d−/− mice, suggesting that CpG-mediated antitumor effect is in part through type II NKT cells. Moreover, the reduction in tumor growth was even greater in CpG-treated WT mice, suggesting that both NKT cell subsets contribute to the antitumor activity of CpG.

Analysis of tumor-infiltrating cells showed that CpG treatment induced a significantly higher percentage of infiltrating CD45+ cells in WT mice than in Jα18−/− and CD1d−/− mice. However, no significant differences in the number and composition of tumor-infiltrating leukocyte subsets were detected between CpG-treated Jα18−/− and CD1d−/− mice (Fig. S6B). Nonetheless, CpG-treated Jα18−/− mice had significantly higher proportions of IFN-γ-producing CD8+ T cells compared with CD1d−/− mice (Fig. S6B). Taken together, our data suggest that type II NKT cells can contribute to the antitumor effect of CpG by augmenting CD8+ T-cell responses.

Discussion
Polyclonal type II NKT cells were initially characterized in MHCII−/− mice. They are a mixture of NKT1+ and NKT1.1+ T cells with a memory phenotype and express particular TCRα chains, such as Vα3.2 and Vα8 (24, 34). In agreement with previous observations, type II NKT cells as defined by GFR+ TCRβ+ cells in Jα18−/−4get mice are a heterogeneous population that contain both NKT1+ and NKT1.1+ cells, most of which are CD4+ and exhibit a preactivated phenotype. Additionally, 4get+ type II NKT cells have a diverse TCRα repertoire, with the Vα8 chain being the most highly represented (Fig. 2D). However, very few type II NKT cells in Jα18−/− 4get mice express Vα3.2. Whether more than 20% of their wild-type counterparts (defined as GFR+ TCRβ+CD1d+GalCer− in 4get mice) are Vα3.2-positive (Fig. S5A). This difference may be due to an unintended effect of gene modification of the Jα18 locus. A recent report has shown that transcription of TCRα gene rearrangements involving J segments upstream of Jα18 is impaired in Jα18−/− mice (35). Despite some differences in their TCRα repertoire, we found that type II NKT cells in Jα18−/− 4get mice closely resemble those from WT mice in terms of their surface phenotype and cytokine-producing capacity (Fig. 4 and Fig. S5B). This supports the validity of using GFR+ TCRβ+ cells in Jα18−/− 4get mice to study the development and function of polyclonal type II NKT cells.

Previous studies with type II NKT cell hybridomas have identified several self-lipid antigens recognized by type II NKT cells, including phospholipids, β-GlCer, and sulfatide (27, 36–40). Interestingly, we found that 4get+ type II NKT cells are potent activators of β-GlCer containing C12:0 and C24:1 acyl chains, suggesting that a significant proportion of type II NKT cells recognize β-GlCer. Therefore, it is conceivable that increased levels of β-GlCer during infection could also lead to type II NKT cell activation. Consistent with a recent study, we found that Lyso-PE has a stimulatory effect on 4get+ type II NKT cells, albeit less potent than β-GlCer (41). In contrast, sulfatide failed to stimulate detectable cytokine response by 4get+ type II NKT cells. Therefore, type II NKT cells defined by this method likely represent a population distinct from those identified by CD1d/sulfatide tetramers. This notion is further
CpG treatment induces IFN-γ production by type II NKT cells is in agreement with a study by Paget et al. (33) showing that splenocytes from CD1d−/− mice produced less IFN-γ compared with Jα18−/− mice in response to either ODN1826 or ODN1668 (Fig. 5 and Fig. S6). However, our findings contradict with a study by Sfondrini et al. (44), which reported that CpG-dependent tumor growth inhibition was only observed in the absence of type II NKT cells in B16 melanoma model and that splenocytes from CD1d−/− mice produced higher levels of IFN-γ compared with Jα18−/− and WT mice upon CpG stimulation. Recent reports suggest that housing conditions may alter the function of type I NKT cells (45). Therefore, it is possible that the conflicting data are a result of such a variable or genetic heterogeneity of mutant mice used in these studies.

The nature and function of type II NKT cells especially on a polyclonal level are poorly understood. In this study we characterized polyclonal type II NKT cells and compared them head to head with type I NKT cells. Our data indicate that type I and type II NKT cells may function differently upon activation. This warrants the study of type II NKT cells in greater depth, especially with evidence showing type II NKT cells as the dominant subset in humans. We also demonstrated the feasibility of manipulating the function of type II NKT cells by CpG and shifting their role from immunosuppressive to protective in tumor immunity. Our data suggest that CpG-activated type II NKT cells have potential to be therapeutically harnessed for cancer treatment.

**Materials and Methods**

**Mice.** Jα18−/−, IL1d−/−, K8.3-KLDCtG, IL-4 GFP enriched transcript (4gett) mice, SAP−/−, and PLZF-deficient luxoid (PLZFlux−/−) mice have been described elsewhere (46–51). 4gett mice were crossed with Jα18−/−CD1d−/− mice to obtain Jα18−/−CD1d−/−4gett mice, which were then intercrossed to generate Jα18−/−4gett and Jα18−/−CD1d+4gett mice, respectively. Jα18−/−4gett mice were further crossed with SAP−/− and PLZFlux+/− mice to generate Jα18−/−SAP−/−4gett and Jα18−/−PLZFlux+/−mice. All mice used in this study were backcrossed to C57BL/6 at least 10 times. All animal work was approved by the Northwestern University Institutional Animal Care and Use Committee.

**Reagents and Antibodies.** CpG ODN 1826 (5′-tcatgctctctgctgacgtt-3′) and ODN 1668 (5′-tcatgctctctgctgacgtt-3′) were synthesized at Integrated Device Technology, CD1d1/GaICer tetramers were provided by the National Institutes of Health tetramer facility. Lipid antigens were obtained from Avanti Polar Lipids. The generation of CD1d-specific mAb SC6 has been described previously (52). Fluorochrome-labeled mAbs against mouse B220, CD4, CD8α, CD11c, CD25, CD44, CD62L, CD90, IL-4, IFN-γ, NK1.1, Ly6G, Fopx3, IL-13, GM-CSF, CD112, ICOS, i7 integrin, CD45RB, TCRβ, Vα3.2, Vα8.3, Vα11.1, Vβ2, Vβ3, Vβ4, Vβ5.1/5.2, Vβ6, Vβ7, Vβ8.1/8.2, Vβ11, Vβ10, Vβ11, Vβ12, and Vβ14 were purchased from eBioscience, BD Biosciences, or BioLegend.

**Flow Cytometry.** For cell surface staining, cells were incubated with anti-CD16/32 mAb before staining with the appropriate combinations of mAbs. PLZF expression was analyzed via intracellular staining using the FoxP3 staining buffer set (eBioscience) with anti-PLZF mAb (Santa Cruz Biotechnology). For intracellular cytokine staining, cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% saponin, and then stained with anti-cytokine mAbs. Flow cytometry was performed with a FACS Canto II (BD Biosciences) and analyzed using FlowJo software (Tree Star).

**Cell Preparations and NKT Cell Sorting.** Cell suspension of thymus, spleen, liver was prepared as described previously (53). BMDCs were prepared using GM-CSF and IL-4 as previously described (48). Tumor-infiltrating cells were isolated by digestion with 1 mg/ml collagenase and 100 μg/ml DNAse at 37 °C for 30 min. For sorting type I NKT cells, hepatic leukocytes from 4gett mice were stained with CD1d1/GaICer tetramers and anti-B220. For sorting type II NKT cells, hepatic leukocytes from Jα18−/−4gett mice were stained with anti-TCRβ. Cells were sorted in a FACS Aria (BD Biosciences). Sorted type I NKT cells (Tet+B220+) and type II NKT cells (TCRβ+GFP+) were then more than 90% pure.

**NKT Cell Stimulation and Cytokine Analysis.** For antigen stimulation, sorted type I and II NKT cell were cultured in vitro for 7 d as described previously (54), except cells were cultured in the medium containing IL-7 (2 U/ml) and IL-15 (50 ng/ml) from day 5 to day 7. NKT cells (0.5–1 x 106 cells) from the short-
B16 Melanoma Model. Mice were inoculated s.c. with 3 x 10^5 B16 melanoma cells. Eight days later, mice were treated with either PBS or CpG ODN1826 (10 μg in 100 μL of PBS) at the tumor site. Two perpendicular diameters of the tumor mass were measured every 2 d, and tumor volumes were calculated as: V = 0.5 x length x width^2.

Statistical Analysis. Mean values were compared using unpaired Student t tests. All statistical analyses were performed using Prism software. Results with a value of P < 0.05 were considered significant.

ACKNOWLEDGMENTS. We thank Dr. Luc Van Kaer for Jlv18/18 mice, Dr. Paul Stein for SAP−/− and 4get mice, Dr. Jonathan Licht for PLP1^Δ2′ mice, the National Institutes of Health (NIH) tetramer core facility for CD1d tetramers, the Northwestern University flow cytometry core facility for cell sorting, and Sharmilla Shannumagad and Ying-He for technical assistance. This work is supported by NIH Grant R01AI34407 and a Cohn's and Collitis Foundation of America Senior Research Award (to C.-R.W.).